Status Epilepticus Mortality Rises in the United States Since 2007

The Rising Stakes of Status Epilepticus Management

Status epilepticus represents a critical neurological emergency, carrying a reported mortality rate of approximately 20% [1]. This state of persistent seizure activity requires immediate intervention to prevent death or permanent neurological sequelae (long-term cognitive or motor deficits resulting from the seizure), which affect an estimated 19.8% of survivors [2]. While benzodiazepines are the established first-line therapy, nearly half of all patients fail to achieve seizure cessation with initial agents [3]. In a randomized trial of 384 patients, second-line treatment with levetiracetam, fosphenytoin, or valproate resulted in seizure termination at 60 minutes in 47%, 45%, and 46% of cases, respectively [4]. Despite these protocols, status epilepticus remains a leading cause of epilepsy-related mortality, accounting for 58.5% of deaths in some populations [5, 6]. To determine if modern clinical interventions are successfully reducing the death toll of this condition, a new large-scale longitudinal study examines two decades of national data, revealing troubling trends that should prompt physicians to reevaluate how they manage high-risk demographic groups.

Two Decades of Shifting Mortality Trends

To evaluate the longitudinal trajectory of mortality associated with this neurological emergency, researchers retrieved data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC-WONDER) database for adults aged 25 years or older. The study calculated both crude rates (the raw number of deaths per 100,000 persons) and age-adjusted mortality rates (a metric standardized to a common age distribution to allow fair comparisons across different populations). To pinpoint exactly when these trends shifted, the authors estimated the annual percent change using joinpoint regression (a statistical method that identifies specific years where a trajectory significantly alters its course). Between 1999 and 2020, a total of 32,174 status epilepticus-related deaths were recorded in the adult population.

A critical finding for practicing physicians is that 83.7% of these recorded deaths occurred within medical facilities. This indicates that while the vast majority of patients are reaching professional care, inpatient mortality remains a severe risk, underscoring the need for optimized hospital protocols and rapid escalation of antiepileptic therapy. The longitudinal analysis revealed a distinct two-phase trend. The age-adjusted mortality rate remained stable from 1999 to 2007, reflecting a period of relative consistency in outcomes.

However, this stability was followed by a troubling shift in the epidemiological landscape. The researchers found that the age-adjusted mortality rate increased steadily from 2007 through 2020. This upward trend over the last thirteen years highlights an escalating clinical challenge in managing status epilepticus. The data suggest that the burden of this condition is growing, necessitating a closer examination of whether current treatment algorithms are being applied aggressively enough to combat the rising mortality rates in the modern clinical era.

Demographic Vulnerabilities in Acute Seizure Outcomes

The analysis highlights a clear correlation between advancing age and the risk of death from prolonged seizures. The researchers found that the highest crude mortality rates occurred among adults aged 65 years or older. Geriatric patients represent the most vulnerable demographic, likely due to a combination of age-related physiological decline, a higher prevalence of comorbid conditions, and a lower threshold for neurological injury during continuous seizure activity. For the practicing clinician, these data underscore the necessity of rapid, aggressive intervention in older adults. The physiological reserve required to withstand the intense metabolic demands of status epilepticus is significantly diminished in this population, meaning delays in administering second-line or third-line antiepileptic drugs could prove fatal.

In addition to age-related risks, the study identified significant differences in outcomes based on biological sex. The data revealed that men showed higher age-adjusted mortality rates than women throughout the 22-year study period. While the underlying mechanisms for this disparity require further investigation, the finding indicates that male patients face a statistically higher risk of fatal outcomes. When combined with the age-related data, these findings provide a clearer profile of the high-risk patient. Physicians should consider these demographic factors when triaging acute seizures, recognizing that older men may require particularly vigilant monitoring in the intensive care unit to mitigate the rising trend in mortality.

Racial and Regional Disparities in Neurological Emergencies

The clinical burden of status epilepticus is substantial, with an incidence ranging from 18.3 to 41 per 1,000 people in the United States. To better understand the factors driving fatal outcomes, the researchers investigated mortality trends stratified by race, ethnicity, and geographic region. The findings revealed that status epilepticus-related mortality in adults has been rising alongside notable demographic disparities. Among the racial groups studied, Non-Hispanic Black individuals had the highest age-adjusted mortality rate. Furthermore, this population experienced the greatest rise in mortality over the 22-year study period, indicating a widening gap in survival outcomes for Black patients presenting with this neurological emergency.

These trends were followed in magnitude by Non-Hispanic White individuals and Hispanic or Latino individuals, who also saw increases in overall mortality rates. Geographic analysis further localized the crisis, showing that the South displayed the highest age-adjusted mortality rate of all United States regions. For the practicing physician, these data suggest that the risk of death from status epilepticus is heavily influenced by systemic and regional factors. These disparities may reflect differences in access to rapid neurological care, emergency medical service response times, or the prevalence of underlying risk factors like medication nonadherence and structural brain disease. Addressing these racial disparities and tailoring acute management strategies for high-risk groups, particularly in the Southern United States, are critical steps to curb the rising mortality associated with this severe condition.

References

1. Dasara M, Dono F, Evangelista G, et al. Status epilepticus as a complication of SARS-CoV-2 vaccination: Two case reports and systematic review with individual patients' data analysis.. Seizure. 2024. doi:10.1016/j.seizure.2024.07.013

2. Geremew GW, Wassie Y, Zeleke TK, et al. Treatment outcome and its predictors among patients with status epilepticus in Africa: A systematic review and meta-analysis. Exploratory Research in Clinical and Social Pharmacy. 2026. doi:10.1016/j.rcsop.2026.100738

3. Cruickshank M, Imamura M, Counsell C, et al. Management of the first stage of convulsive status epilepticus in adults: a systematic review of current randomised evidence. Journal of Neurology. 2022. doi:10.1007/s00415-022-10979-2

4. Kapur J, Elm J, Chamberlain JM, et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. New England Journal of Medicine. 2019. doi:10.1056/nejmoa1905795

5. Fodjo JNS, Cutsem GV, Amaral L, Colebunders R. Mortality among persons with epilepsy in onchocerciasis-endemic and non-endemic areas of sub-Saharan Africa: A systematic review and meta-analysis.. Seizure. 2023. doi:10.1016/j.seizure.2023.07.006

6. Levira F, Thurman DJ, Sander JW, et al. Premature mortality of epilepsy in low- and middle-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy.. Epilepsia. 2017. doi:10.1111/epi.13603